SNDX — Syndax Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.85bn
- $1.27bn
- 36
- 22
- 76
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.33 | ||
| Price to Tang. Book | 3.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.45% | ||
| Return on Equity | -40.98% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.52 | 1.52 | 139.71 | n/a | n/a | 29.47 | 129.01 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Directors
- Dennis Podlesak NEC (63)
- Michael Metzger PRE (50)
- Alexander Nolte CFO (49)
- Luke Albrecht SVP (42)
- Michael Meyers SVP (71)
- Peter Ordentlich CSO (52)
- Martin Huber DRC (61)
- Briggs Morrison DRC (62)
- Fabrice Egros IND (59)
- Jennifer Jarrett IND (50)
- Keith Katkin IND (49)
- Pierre Legault IND (62)
- William Meury IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 11th, 2005
- Public Since
- March 3rd, 2016
- No. of Shareholders
- 20
- No. of Employees
- 112
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 84,979,686
- Address
- 35 Gatehouse Drive, Building D, Floor 3, WALTHAM, 02451
- Web
- https://syndax.com/
- Phone
- +1 7814191400
- Auditors
- Deloitte & Touche LLP
Upcoming Events for SNDX
Q1 2024 Syndax Pharmaceuticals Inc Earnings Release
Syndax Pharmaceuticals Inc Annual Shareholders Meeting
Syndax Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Syndax Pharmaceuticals Inc Earnings Release
Similar to SNDX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Syndax Pharmaceuticals share price?
As of Today at 19:21 UTC, shares in Syndax Pharmaceuticals are trading at $21.72. This share price information is delayed by 15 minutes.
How has the Syndax Pharmaceuticals share price performed this year?
Shares in Syndax Pharmaceuticals last closed at $21.72 and the price had moved by +7.52% over the past 365 days. In terms of relative price strength the Syndax Pharmaceuticals share price has underperformed the S&P500 Index by -13.16% over the past year.
What are the analyst and broker recommendations for Syndax Pharmaceuticals?
The overall consensus recommendation for Syndax Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Syndax Pharmaceuticals dividend yield?
Syndax Pharmaceuticals does not currently pay a dividend.
Does Syndax Pharmaceuticals pay a dividend?
Syndax Pharmaceuticals does not currently pay a dividend.
When does Syndax Pharmaceuticals next pay dividends?
Syndax Pharmaceuticals does not currently pay a dividend.
How do I buy Syndax Pharmaceuticals shares?
To buy shares in Syndax Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Syndax Pharmaceuticals?
As of the previous close price of $21.72, shares in Syndax Pharmaceuticals had a market capitalisation of $1.85bn.
Where are Syndax Pharmaceuticals shares listed?
Here are the trading details for Syndax Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SNDX
What kind of share is Syndax Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Syndax Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Syndax Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Syndax Pharmaceuticals is $35.27. That is 62.38% above the last closing price of $21.72.
Analysts covering Syndax Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$3.87 for the next financial year.
What is the trend in the Syndax Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Syndax Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +54.64%.
As of the last closing price of $21.72, shares in Syndax Pharmaceuticals were trading +13.98% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Syndax Pharmaceuticals PE Ratio?
The Syndax Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $21.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Syndax Pharmaceuticals?
Syndax Pharmaceuticals' management team is headed by:
- Dennis Podlesak - NEC
- Michael Metzger - PRE
- Alexander Nolte - CFO
- Luke Albrecht - SVP
- Michael Meyers - SVP
- Peter Ordentlich - CSO
- Martin Huber - DRC
- Briggs Morrison - DRC
- Fabrice Egros - IND
- Jennifer Jarrett - IND
- Keith Katkin - IND
- Pierre Legault - IND
- William Meury - IND